Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Elan blocks Royalty takeover – for now

After rejecting Royalty Pharma's bid Elan wants greater clarity on the deal

- PMLiVE

Roche is drawn to science for YouTube campaign

Therapeutic antibodies, stem cells and Zebrafish tackled in series of fun videos

- PMLiVE

Alexza’s Peter Schineller joins Agendia

Appointed first chief commercial officer

- PMLiVE

Talking about a successful merger

How communications can support effective mergers and acquisitions outcomes

ApotheCom ScopeMedical expands team

ApotheCom ScopeMedical names new members of its senior management team

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

- PMLiVE

GSK’s Tyverb/ Tykerb disappoints in gastric cancer trial

Fails to improve overall survival in proposed new indication

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

- PMLiVE

Kite Pharma appoints Zelboraf scientist as CMO

Keith Nolop joins US cancer biotech from Plexxikon

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links